Kornimate/medical-research-clean huggingface dataset:
impact of the ct scan in patients with suspected covid-19

Conditions: COVID-19

Summary: the diagnostic performance of the scanner in the indication of suspected covid-19 is not yet well known, especially in comparison with the results of rt-pcr. the potential use of the scanner as a tool for quantifying the severity of covid-19 disease is not yet well established, especially the variations between readers or between measurement techniques. the impact of the scanner in predicting the fate of patients with confirmed covid-19 is not yet known.


Eligibility criteria:
inclusion criteria * adult patient (≥18 years old) * patient admitted to strasbourg university hospitals for suspicion of covid-19, between 03/01/2020 and 04/29/2020 * availability of at least one chest ct scan during hospitalization * subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. non-inclusion criteria * patient who expressed his opposition to participating in the study * patient under legal protection * patient under guardianship or guardianship

Keywords: covid-19 sars-cov-2 chest scanner ct scan rt-pcr
observational study in patients treated with jak inhibitors for inflammatory rheumatism (majik)

Conditions: Rheumatoid Arthritis; Inflammatory Rheumatism; Psoriatic Arthritis; Spondyloarthritis

Summary: janus kinase (jak) inhibitors are a new class of molecules available to the therapeutic arsenal for chronic inflammatory rheumatic diseases.the tolerance profile of this new class needs to be better defined and its use in real life further established. the french society of rheumatologists intends to coordinate a prospective national registry study for this follow-up. this registry will include at least 1500 rheumatoid arthritis (ra) and 150 patients with psoriatic arthritis from the start of treatment with jak inhibitor and then followed for 5 years. this registry is a longitudinal, multicentre, observational registry study. the objective of this national registry is to get a better understanding of the safety profiles of jak inhibitors and get knowledge of their use in daily practice in order to optimize this use and potentially integrate jak inhibitors into personalised medicine strategies. this registry will generate efficacy data, especially therapeutic maintenance, observation, allowing inter-registry comparisons with other biologic compounds in the french population, and can be aggregated with other similar registries in other countries.

design: this registry is a longitudinal, multicentre, observational registry study, with continuous and ambispective collection of clinical and laboratory data. the patients will be followed for 5 years, regardless of the therapeutic modifications occurring thereafter. target population: patients initiating jak inhibitor therapy for inflammatory rheumatic disorder. number of patients and centres : * the objective is to include, per drug available on the market, at least 300 to 500 patients with ra and at least 100 to 150 patients with psoriatic arthritis. if a jak inhibitor is approved in a new indication of chronic rheumatic disease by european medicines agency (ema), the number of patients to include for each molecule in this indication will be adjusted as a function of the prevalence/epidemiology of each disease. products currently available (baricitinib and tofacitinib) will be considered at the start of this registry; then every new indication for an already approved drug or every new drug in the same therapeutic class starting from the date they are placed on the market will be considered. * more than 80 centers in france (hospital-based, public and private practice) will participate.

Eligibility criteria:
inclusion criteria * patients older than 18 * patient treated with a jak inhibitor in accordance with ema, for chronic inflammatory rheumatisms, independent of the therapeutic line * subject who is a member of a social security regime * free, declared, written consent signed by the subject and the investigator on the day of inclusion exclusion criteria * patient who cannot understand the implications and rules of the study * patient opposition to participating in the study
rhgh therapy on hepatic drug metabolism

Conditions: Growth Hormone Deficiency, Dwarfism

Summary: the purpose of the study is to understand the effect of rhgh therapy on hepatic drug metabolism in children with idiopathic growth hormone deficiency.

growth hormone (gh) deficiency is a prominent cause of short stature, affecting approximately 14,000 children in the us. although a single study has demonstrated reduces cyp1a2 activity following gh replacement therapy, the effect of gh on the most abundant phase 1 biotransformation pathways (e.g. cyp2d6 and cyp3a4) remain largely uncharacterized. this information gap exists largely due to the lack of sufficiently safe, specific and non-invasive methods appropriate for the longitudinal evaluation of enzyme activity in young children. we can overcome these problems by employing validated phenotyping methods using caffeine, a commonly ingested dietary substance and dextromethorphan, a safe, non-sedating over the counter anti-tussive agent. application of these methods will permit us to identify, characterize and describe the isoform-specific effects of rhgh on major phase 1 hepatic drug biotransformation pathways, thereby addressing this information gap with minimal risk to children.

Eligibility criteria:
inclusion criteria: * children ages 4 to 14 years with a height less than the 5th percentile for age and sex or having a decelerated across two major percentiles (5th, 10th, 25th, 50th, 90th, and 95th) on standard pediatric growth curves, poor growth velocity (less than 5 centimeters/year), radiographic evidence of delayed bone age (i.e. greater than 1 sd below the mean for chronological age) and a documented diagnosis of idiopathic growth hormone deficiency \[as determined by failure to raise serum gh concentrations 10 microgram/liter following provocative testing with two growth hormone secretagogues(e.g. insulin, arginine, or clonidine)\]. * all subjects will be prepubertal, as determined by tanner staging. exclusion criteria: * children receiving medications known to induce or inhibit hepatic cyp1a2, nat-2, xo, cyp2d6 or cyp3a4 activity. * subjects with a history of smoking (including exposure to second hand smoke \> 8 hours per day) or illicit drug use. * subjects with a history of hepatic, renal, cardiac or thyroid disorders. presence of hepatic, renal, cardiac or thyroid disease will be established based on clinical history and results of recent laboratory tests conducted as part of the routine medical evaluation of children who are being considered for rhgh therapy. * children experiencing fever or acute viral illness * children who have a history of a hypersensitivity reaction to dextromethorphan or caffeine * children who have received prior treatment with rhgh * children who are receiving corticosteroids or thyroid hormone

Keywords: recombinant human growth hormone growth hormone deficiency short stature phenotyping
a clinical research studying interventions for nighttime fears in preschool children

Conditions: Nighttime Fears

Summary: nighttime fears (ntf) and sleep disruptions in preschool children continue to be major problems in clinical services. the aim of this study is to test the efficacy of two interventions designed for preschool children suffering from ntf: (a) a cbt adaptation combining parent involved play, which will include multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management; and (b) triadic expressive play therapy, based on virginia axline's (1947) eight basic principles of play therapy. parents will take an active part both in and in between treatment sessions in both intervention groups. in addition to the review of the outcomes of these interventions, the proposed study aims to identify variables that moderate and mediate treatment effects. in an attempt to meet these aims, the investigators will recruit 90 children suffering severe ntf and their parents who seek treatment. at baseline the investigators will assess children's ntf and general fears, sleep patterns and disruptions, behavior problems and potential moderators (i.e. playfulness, oppositionality, desire for control and parental anxiety). assessment will be based on both objective and subjective measures, including interviews with the child and parents, questionnaires and actigraphy. the investigators will then randomly assign these children to one of two conditions: cbt with parent involved play or triadic expressive play therapy. possible mediators (i.e. the therapeutic alliance, patient compliance, motivation etc.) will be evaluated after each of the active intervention sessions. the effects of the interventions will be assessed by comparing four time points: baseline, first week of intervention, 1 month and 6 months subsequent to administration. the main hypotheses of the proposed study are: (a) a positive correlation will be found between the severity of ntf and the severity of sleep disruption at baseline, and a reduction in ntf will be associated with an improvement in sleep; (b) both interventions will significantly reduce nighttime fears, but greater impact will be evident in the cbt group; (c) higher levels of playfulness and lower levels of oppositionality and desire for control, as well as parental anxiety will predict desirable outcomes. (d) stronger therapeutic alliances, in addition to higher levels of motivation and compliance will be associated with greater intervention effectiveness.


Eligibility criteria:
inclusion criteria: * ntf exist for a minimum of 2 months, with significant adverse impact on the child and the family, requiring parental involvement for at least two nights per week to comfort the child. exclusion criteria: * major health or neurological-developmental problems * concurrent psychiatric treatment * concurrent psychotherapy or any other intervention aimed at reducing the child's nighttime fears.

Keywords: nighttime fears anxiety sleep actigraphy intervention
fructose malabsorption in northern norway

Conditions: Irritable Bowel Syndrome; Fructose Malabsorption

Summary: different published studies has shown a possible co-variation between leakage of fructose to the great bowel and exacerbation of irritable bowel syndrome (ibs) symptoms. the aim of the finn trial is to study the role of fructose malabsorption in patients with ibs in order to evaluate different diagnostic criteria for fructose malabsorption and at the same time study the effect of diet treatment in this cohort of patients and estimate the prevalence of fructose malabsorption.


Eligibility criteria:
inclusion criteria: * ibs patients satisfying rome 2 diagnostic criteria exclusion criteria: * seriously ill * organic abdominal disease * other functional bowel disease

Keywords: fructose irritable bowel syndrome malabsorption glut5 transporter gene
aachen safety and efficacy of the percutaneous transvenous mitral annuloplasty device to reduce mitral regurgitation

Conditions: Heart Failure; Mitral Regurgitation

Summary: improvement in heart failure with moderate to severe mitral regurgitation using a percutaneously delivered implanted device


Eligibility criteria:
inclusion criteria: * symptomatic heart failure * functional mr 2+ - 4+ * lvef 20% - 50% exclusion criteria: * mr of organic origins * significant co-morbidities

Keywords: heart failure mitral regurgitation
study of the angiogenesis by pet/ct in patients with lymphoma

Conditions: Lymphoma

Summary: the aim of the study is to measure tumoral angiogenesis modifications by rgd-k5 pet/ct before and after 2 cycles of chemotherapy in patients with lymphoma and a large tumoral mass

after inclusion pet scans with fdg tracer and with a specific tracer of angiogenesis will be performed on patient with lymphoma. after two cycles of chemotherapy pet scans with the same tracers will be performed. overall survival and disease free survival will be monitored during 18 months.

Eligibility criteria:
inclusion criteria: * male or female * age ≥ 18 years old * oms ≤ 1 * histological diagnosis of diffuse large b-cell lymphoma what ever the subtype * presence of measurable tumor with at least a node mass superior to 3 centimeters * stage i to iv * inform consent signed exclusion criteria: * primary cerebral lymphoma * absence of fixing on fdg-pet exam * pregnant , child bearing, breast feeding or without effective contraception method woman * hypersensitivity to rgd-k5 * hypersensitivity to fdg * poorly controlled diabètes (glycemia ≥ 10 millimoles/liter) * neoplastic disease (less than 2 years or in progression)

Keywords: lymphoma, angiogenesis, pet scan
pathophysiology and treatment of cerebrospinal hypotension exploration study

Conditions: Spontaneous Intracranial Hypotension; Intracranial Hypotension; Post-Lumbar Puncture Headache

Summary: the goal of this observational study is to learn about the effects of a low-pressure environment on the brain in patients with intracranial hypotension and to potentially improve diagnostics and treatment of this condition. the primary objective will be: to investigate the change in clinical biomarkers measured before and after successful treatment. the secondary objectives will be: to investigate if clinical biomarkers can predict the outcome of treatment. participants undergoing standard treatment for intracranial hypotension will undergo additional examinations and surveys and will be followed up for a year for the study.


Eligibility criteria:
inclusion criteria (patients): * age 18-80. * patients with a suspected intracranial hypotension diagnosis. * participants must read and understand the danish language or have an official interpreter present to be able to understand the work-up and sign the participation consent for the study. inclusion criteria (control): * age 18-80. * healthy people who do not suffer from any form of primary headache except infrequent tension-type headache. * participants must read and understand the danish language or have an official interpreter present to be able to sign the participation consent for the study. exclusion criteria (patients): * pregnant or breastfeeding females * patients in whom the examination cannot be performed due to anatomical reasons such as severe head dysmorphia or severe ophthalmological diseases. * the patient has a disease, takes medication, or abuses alcohol or drugs that could, in the investigator´s opinion interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study. * the patient is, in the investigator´s opinion, unlikely to comply with the protocol or is unsuitable for any reason. exclusion criteria (control): * pregnant or breastfeeding females * participants in whom the examination cannot be performed due to anatomical reasons such as severe head dysmorphia or severe ophthalmological diseases. * the participant has a disease, takes medication, or abuses alcohol or drugs that could, in the investigator´s opinion interfere with the interpretation of the study.

Keywords: spontaneous intracranial hypotension sih post-lumbar puncture headache plph danish headache center post-dural puncture headache pdph
the role of sodium bicarbonate as adjuvant treatment of computed tomography identified covid-19 pneumonia

Conditions: Pneumonia; Covid19

Summary: to report the possible role of s.b 8.4% in the treatment of covid-19pneumonia.


Eligibility criteria:
inclusion criteria: * age \>18 years. * fever ≥ 38º c with upper respiratory tract manifestations, generalized bone ache with or without gastrointestinal symptoms as diarrhea. * chest ct with signs suggestive of covid-19. * mild and moderate cases of covid-19 pneumonia with respiratory and hemodynamic stability. - high c reactive protein (crp).- with or without history of contact with index case who is isolated in a governmental hospital assigned for treatment of patients proved to have rt-pcr positive test for covid-19 * with or without abnormalities in the total or differential white cell count. * welling to sign a fully informed consent. exclusion criteria: * severe and critical illness with respiratory failure and/ or hemodynamic instability. * ct with pleural effusion with or without lung cavitation. * other organ failure.

Keywords: covid-19
clinical study of a novel sliding compression locking plate in the treatment of fresh femoral neck fractures

Conditions: Fracture of Femoral Neck

Summary: to verify the safety and efficacy of sliding compression locking plates in the treatment of fresh femoral neck fractures


Eligibility criteria:
inclusion criteria: 1. age \>=18 years old, gender is not limited; 2. patients diagnosed with femoral neck fracture; 3. patients with indications for internal fixation of femoral neck fracture and able to tolerate surgery; 4. the subject or his legal representative is informed of the nature of the study and agrees to participate in the study. exclusion criteria: 1. participants who had participated in clinical studies of other drugs, biologics or medical devices before enrollment and did not reach the primary study endpoint time limit; 2. the patient is known to have a history of allergy to one or more implanted materials; 3. patients determined by researchers to be physically weak or unable to tolerate surgery due to other systemic diseases; 4. active infection of the hip joint or other parts of the body is determined by the investigator; 5. diagnosed as metabolic bone disease, radiation bone disease, etc.; 6. severe hip contracture deformity or severe muscle loss fused to the functional position for a long time without pain; 7. have inflammatory arthritis, such as rheumatoid arthritis, systemic lupus erythematosus arthritis, ankylosing spondylitis, etc.; 8. the patient is mentally incapable or unable to understand the requirements of participating in the study, and it is difficult to cooperate; 9. other conditions deemed unsuitable for inclusion by the investigator.

Keywords: fracture of neck of femur, sliding compression locking plate, compression screws
real world study of regorafenib versus fruquintinib in colorectal cancer

Conditions: Colorectal Cancer

Summary: this is an observational, ambispective cohort study. the aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in china. about 268 eligible metastatic colorectal cancer patients after second-line therapy will be assigned to receive either regorafenib or fruquintinib, based on decision of the gastrointestinal physician according the patients' condition.


Eligibility criteria:
inclusion criteria: 1. signed and dated informed consent. 2. diagnosis of histologically confirmed colorectal cancer, stage iv. 3. after second-line therapy. 4. gastrointestinal physician prescribed to receive regorafenib or fruquintinib according the patients' condition. exclusion criteria: 1. received regorafenib or fruquintinib before third-line therapy. 2. the clinicopathological characteristics and previous therapy were unknown. 3. regorafenib or fruquintinib treatment is less than one cycle in the historical cohort.

Keywords: targeted therapy ttf os pfs ae
characterization of the pattern of consumption and withdrawal syndrome from dual cannabis and tobacco use

Conditions: Cannabis Dependence; Tobacco Use; Withdrawal Syndrome; Substance Abuse

Summary: aims: to characterize the pattern of cannabis and tobacco use and withdrawal symptoms in people who start treatment for cannabis use disorders (exclusive cannabis, concurrent and/or simultaneous with various tobacco products) through an aplication game and considering the type of users. methodology: mixed-methods research composed of three studies. study i: qualitative participatory action study aimed at exploring the experiences and preferences of the cannabis users on the use of apps. this information will be instrumental in the co-design of the app. study ii: prospective longitudinal study aimed to establish consumption patterns and transitions between substances and to validate the scale of cannabis withdrawal symptoms in the spanish population. sample size: expected rr=1.20, α =0.05, β= 0.20, losses= 20% (n=282). study iii: qualitative study to explore participants' experiences during the process of quitting cannabis and / or tobacco. expected results: characterization and prediction of variables that influence cannabis and tobacco cessation/ reduction and describe withdrawal symptoms according to consumption patterns with aim of improving the design of future interventions.


Eligibility criteria:
inclusion criteria: * smokers (at least 1cig./week) * undertreatment for cannabis * \>=18 years-old * under clinical follow-up * informed consent * have a smartphone exclusion criteria: * severe cognitive impairment * 3-month follow-up not guaranteed

Keywords: cannabis tobacco treatment social network
posterior narrow diameter implants in hyperglycemic and normo-glycemic patients

Conditions: Diabetes Mellitus, Type 2; Implant Complication

Summary: the aim of the present study was to compare the initial healing and long term performance of narrow diameter implants in patients with uncontrolled diabetes mellitus type 2 (t2dm) and healthy individuals.


Eligibility criteria:
inclusion criteria: patients with one or more missing teeth posterior to the canine either in the maxilla or mandible and associated with diminished alveolar ridge dimensions were included in the study exclusion criteria: * immobility of diabetic patients * periodontal surgery and/or antibiotic therapy within the last 6 months prior to baseline * pregnancy and lactation period * full mouth plaque score (fmps) \> 25% * untreated periodontitis * smoking \> 10 cigarettes/day * insufficient crestal volume making an augmentation procedure necessary * previously performed ridge augmentation procedure for a staged implant placement * permanent medication potentially affecting blood perfusion rate and bone metabolism
intra-articular injection of allogeneic platelet rich plasma (prp) for adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: the purpose of this study is to compare the efficacy of intra-articular allogenic platelet rich plasma injection and steroid injection in the treatment of adhesive capsulitis of the shoulder.


Eligibility criteria:
inclusion criteria: 1. male or female 18 years of age and older 2. patients who have had pain at least for 12 months 3. limitation of both active and passive movements of the glenohumeral joint of ≥25% in at list 2 directions (abduction,flexion,external rotation,internal rotation), as compared with the contralateral shoulder in the scapular plane and in progressive degree of horizontal adduction exclusion criteria: 1. patients with concurrent bilateral shoulder pain 2. patients with diabetes mellitus 3. patient with overt hypothyroidism or hyperthyroidism 4. patients who received any drug by intra-articular injection for treatment within 6 months prior to this enrollment. 5. patients who have a history of shoulder trauma including dislocation- subluxation- and fracture- breast cancer- or surgery around shoulder- neck and upper back 6. patients with neurological deficit 7. patients who have a history of allergic adverse reactions to corticosteroid 8. patients with secondary adhesive capsulitis 9. patients with systemic inflammatory disease including rheumatoid arthritis 10. patients with degenerative arthritis, infectious arthritis of shoulder joint 11. patients who have a history of shoulder trauma including dislocation, fracture 12. patients taking anticoagulants 13. patients who have a full-thickness rotator cuff tear 14. patients who are difficulty participating in data collection due to communication problem and serious mental illness 15. pregnant women or lactating mothers 16. patients with cerebrovascular accident 17. patients with symptomatic cervical spine disorders 18. patients with serious condition which can affect this study such as severe cardiovascular diseases- renal diseases- liver diseases- endocrine diseases- and cancers